Aerovate Therapeutics Inc (AVTE)
20.19
-1.72
(-7.85%)
USD |
NASDAQ |
May 20, 16:00
20.19
0.00 (0.00%)
After-Hours: 17:26
Aerovate Therapeutics Enterprise Value: 493.25M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 493.25M |
| May 16, 2024 | 531.86M |
| May 15, 2024 | 505.93M |
| May 14, 2024 | 456.09M |
| May 13, 2024 | 452.06M |
| May 10, 2024 | 471.93M |
| May 09, 2024 | 521.77M |
| May 08, 2024 | 505.30M |
| May 07, 2024 | 488.06M |
| May 06, 2024 | 493.23M |
| May 03, 2024 | 483.75M |
| May 02, 2024 | 496.97M |
| May 01, 2024 | 499.55M |
| April 30, 2024 | 475.70M |
| April 29, 2024 | 491.22M |
| April 26, 2024 | 525.70M |
| April 25, 2024 | 520.53M |
| April 24, 2024 | 509.90M |
| April 23, 2024 | 567.95M |
| April 22, 2024 | 537.77M |
| April 19, 2024 | 534.33M |
| April 18, 2024 | 521.39M |
| April 17, 2024 | 547.26M |
| April 16, 2024 | 579.44M |
| April 15, 2024 | 627.72M |
| Date | Value |
|---|---|
| April 12, 2024 | 626.00M |
| April 11, 2024 | 650.86M |
| April 10, 2024 | 654.21M |
| April 09, 2024 | 683.23M |
| April 08, 2024 | 639.43M |
| April 05, 2024 | 599.53M |
| April 04, 2024 | 712.52M |
| April 03, 2024 | 713.08M |
| April 02, 2024 | 725.91M |
| April 01, 2024 | 758.55M |
| March 28, 2024 | 701.47M |
| March 27, 2024 | 671.66M |
| March 26, 2024 | 592.25M |
| March 25, 2024 | 628.47M |
| March 22, 2024 | 595.87M |
| March 21, 2024 | 602.00M |
| March 20, 2024 | 596.34M |
| March 19, 2024 | 591.62M |
| March 18, 2024 | 610.22M |
| March 15, 2024 | 618.83M |
| March 14, 2024 | 551.92M |
| March 13, 2024 | 626.60M |
| March 12, 2024 | 547.75M |
| March 11, 2024 | 565.24M |
| March 08, 2024 | 613.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
34.01M
Minimum
Jan 21 2022
758.55M
Maximum
Apr 01 2024
310.97M
Average
304.39M
Median
Enterprise Value Benchmarks
| Insmed Inc | 4.248B |
| Annexon Inc | 135.20M |
| CEL-SCI Corp | 63.47M |
| AIM ImmunoTech Inc | 7.729M |
| IGC Pharma Inc | 34.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.19M |
| Total Expenses (Quarterly) | 24.62M |
| EPS Diluted (Quarterly) | -0.83 |
| Earnings Yield | -15.06% |